Bibliographic citations
This is an automatically generated citacion. Modify it if you see fit
Flemming, C., (2019). Gestión por procesos y la cadena de valor en la industria farmacéutica [Trabajo de suficiencia profesional, Universidad de Lima]. https://hdl.handle.net/20.500.12724/10543http://doi.org/10.26439/ulima.tesis/10543
Flemming, C., Gestión por procesos y la cadena de valor en la industria farmacéutica [Trabajo de suficiencia profesional]. PE: Universidad de Lima; 2019. https://hdl.handle.net/20.500.12724/10543http://doi.org/10.26439/ulima.tesis/10543
@misc{sunedu/3306271,
title = "Gestión por procesos y la cadena de valor en la industria farmacéutica",
author = "Flemming Abad, César Germán",
publisher = "Universidad de Lima",
year = "2019"
}
Title: Gestión por procesos y la cadena de valor en la industria farmacéutica
Authors(s): Flemming Abad, César Germán
Advisor(s): Urbina Rivera, Carlos Medardo
Keywords: Manufacturing processes; Pharmaceutical industry; Industria farmacéutica; Procesos de fabricación; Laboratorios farmacéuticos; Drug factories
OCDE field: http://purl.org/pe-repo/ocde/ford#2.00.00
Issue Date: 2019
Institution: Universidad de Lima
Abstract: Desde el año 2015 se ha llevado a cabo un trabajo de análisis y desarrollo en el que han
participado líderes científicos, investigadores clínicos, gestores de la investigación y
responsables tanto del sector público como del privado dirigido a implementar una nueva
línea de negocios en los Laboratorios G y F Farma, involucrando a los principales
Stakeholders en la industria farmacéutica peruana en el que se formado parte activa con
los líderes gerenciales a cargo que representan a las diversas áreas en comercialización y
producción, del sector farmacéutico público y privado.
Durante el desarrollo del proyecto se identificó la necesidad de contar con medicamentos
que no se encuentran disponibles en el mercado peruano y se habían convertido en una
barrera para el desarrollo de otras líneas de trabajo; así como también se identificó la
necesidad de implementar herramientas de Ingeniería Industrial que no se utilizaban en
el estilo cotidiano del trabajo que se venía realizando en la empresa analizada, habiéndose
convertido en una gran limitante.
Con este objetivo se constituyó la línea de Productos Estratégicos Hospitalarios (PEH),
la cual en un primer momento (con una línea antecesora) se direccionó a productos
relacionados a las especialidades como sector onco-hematológico, oncológico,
endocrinológico y en su posterior desarrollo se identificó otras especialidades y
necesidades en ambos sectores, en la especialidad de Enfermedades Huérfanas y Raras
(EHR).
Since 2015, an analysis and development work has been carried out in which scientific leaders, clinical researchers, research managers and managers from both the public and private sectors have participated, aimed at implementing a new line of business in the Laboratories G and F Farma, involving the main Stakeholders in the Peruvian pharmaceutical industry in which they actively participated with the managerial leaders in charge representing the various areas in marketing and production, in the public and private pharmaceutical sector. During the development of the project, the need for medicines that are not available in the Peruvian market and that had become a barrier to the development of other lines of work was identified; as well as the need to implement Industrial Engineering tools that were not used in the daily style of work that had been done in the analyzed company, having become a great limitation. With this objective, the Hospital Strategic Products (PEH) line was established, which initially (with a predecessor line) addressed products related to specialties such as oncohematological, oncological, endocrinological and later development. He identified other specialties and needs in both sectors, in the specialty of Orphan and Rare Diseases (EHR).
Since 2015, an analysis and development work has been carried out in which scientific leaders, clinical researchers, research managers and managers from both the public and private sectors have participated, aimed at implementing a new line of business in the Laboratories G and F Farma, involving the main Stakeholders in the Peruvian pharmaceutical industry in which they actively participated with the managerial leaders in charge representing the various areas in marketing and production, in the public and private pharmaceutical sector. During the development of the project, the need for medicines that are not available in the Peruvian market and that had become a barrier to the development of other lines of work was identified; as well as the need to implement Industrial Engineering tools that were not used in the daily style of work that had been done in the analyzed company, having become a great limitation. With this objective, the Hospital Strategic Products (PEH) line was established, which initially (with a predecessor line) addressed products related to specialties such as oncohematological, oncological, endocrinological and later development. He identified other specialties and needs in both sectors, in the specialty of Orphan and Rare Diseases (EHR).
Link to repository: https://hdl.handle.net/20.500.12724/10543; http://doi.org/10.26439/ulima.tesis/10543
Discipline: Ingeniería Industrial
Grade or title grantor: Universidad de Lima. Facultad de Ingeniería y Arquitectura
Grade or title: Ingeniero Industrial
Register date: 6-Mar-2020; 6-Mar-2020
This item is licensed under a Creative Commons License